Transglutaminase 6

Polyclonal antibody to human neuronal transglutaminase (TG6)



Order
Quantity
Price
Status
250 µg 400 € available


Art. No. A156
Background info Polyclonal antibody to human TG6 A156 replaces Polyclonal antibody A017 which is sold out.
Host Rabbit
Immunogen Human neuronal transglutaminase (full-length protein with N-terminal hexahistidin-tag) recombinantly produced in insect cells.
Specificity A156 is specific to human TG6.
Specificity of A156 was determined with human transglutaminases (TG1 – TG7, FXIII) with ELISA technique.
Formulation The antibody is lyophilized from 250 μL 10 mM sodium phosphate buffer pH 8.1, 150 mM NaCl, 2 mg/mL human serum albumin, azide free.
Working dilutions Optimal dilutions should be determined by the end user.
E.g. for Western-Blotting: 1 / 500 to 1 / 5,000 should be suitable
Reference(s) Tripathy et al., Hum. Mol. Genet. 2017, 26:3749-62;
Schulze-Krebs et al., Brain Res. 2016, 1631:22-33
Note INTENDED FOR RESEARCH USE ONLY, NOT FOR USE IN HUMAN, THERAPEUTIC OR DIAGNOSTIC APPLICATIONS.

Products

  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.

News  

  • Zedira publication - Features of ZED1227: The First-In-Class Tissue Transglutaminase Inhibitor Undergoing Clinical Evaluation for the Treatment of Celiac Disease
  • Dr. Falk Pharma and Zedira announce start of the phase 2b real-life study of ZED1227 for the treatment of Celiac Disease
  • imageDr. Falk Pharma and Zedira announce successful completion of the phase 2a proof-of-concept study of ZED1227 for the treatment of Celiac Disease
  • imageDr. Falk Pharma und Zedira verkünden den erfolgreichen Abschluss der Phase 2a-Studie mit ZED1227 zur Behandlung von Zöliakie
  • imageReversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis
  • imagePress release: Zedira announces ISO 9001:2015 certification

Blog  

  • DZG Aktuell: „Aufruf zur Teilnahme an einer weiteren Wirksamkeitsstudie mit dem Studienmedikament ZED1227“
  • imageDesign of Oral FXIIIa Blockers as Safer Anticoagulants – Mission Impossible?
  • imageMicrobial transglutaminase (MTG) enables efficient and site-specific conjugation to native antibodies without the need of antibody engineering

Events

  • 19th International Celiac Disease Symposium

    19.10.2022 - 22.10.2022
    Sorrento, Italy